ライフサイエンスコーパス: protease-activated receptor 1

1 dependent stimulation of the MAPK pathway by protease activated receptor 1.

2 own for epidermal growth factor receptor and protease activated receptor-1.

3 elium in vivo and in vitro by acting through protease-activated receptor 1.

4 ry neurons in the skin through activation of protease-activated receptor 1.

5 lococcus aureus triggering itch via neuronal protease-activated receptor 1.

6 ities via endothelial protein C receptor and protease-activated receptor-1.

7 endent on endothelial protein C receptor and protease-activated receptor-1.

8 or, endothelial cell protein C receptor, and protease-activated receptor-1.

9 duced by activation of the thrombin receptor protease-activated receptor-1.

10 nts of the transforming pathway initiated by protease-activated receptor-1.

11 mplex in response to signals transduced from protease-activated receptor-1.

12 pression of Card10 mRNA and protein, but not protease-activated receptor-1.

13 dependent lysosomal trafficking of the GPCR, protease-activated receptor-1.

14 rating factor Xa for thrombin generation and protease activated receptor 1/2 heterodimer signaling.

15 Protease-activated receptors 1-3 (PAR1, PAR2, and PAR3)

16 Thrombin ligation of protease-activated receptor-1 activated the phosphorylat

17 ar cell recruitment in vivo was dependent on protease-activated receptor-1 activation of the MEK/ERK/

18 at endothelial cells with thrombin or murine protease-activated receptor 1 agonist peptide resulted i

19 o acetylcholine, 5-hydroxytryptamine, or the protease-activated receptor-1 agonist peptide TFFLR.

20 nery, because these responses are induced by protease-activated receptor-1 agonists and phospholipase

21 Zn(2+) enhanced APC-mediated activation of protease activated receptor 1 and p44/42 MAPK.

22 normal antiapoptotic activity that requires protease activated receptor-1 and endothelial cell prote

23 ated through G(i)-coupled receptors, such as protease-activated receptor 1 and CXC chemokine receptor

24 secreted matrix metalloproteinase 1 binds to protease-activated receptor 1 and integrin alphaVbeta5 o

25 d receptor 4 in human podocytes, and between protease-activated receptor 1 and protease-activated rec

26 otease-activated receptor 4, and between rat protease-activated receptor 1 and protease-activated rec

27 larization and neurogenesis were mediated by protease-activated receptor 1 and were independent of th

28 apoptosis of human brain endothelial cells, protease-activated receptor-1 and endothelial protein C

29 n vivo evidence for the physiologic roles of protease-activated receptor-1 and endothelial protein C

30 of thrombin was attenuated by application of protease-activated receptor-1 and protein kinase C antag

31 These effects require protease-activated receptor-1 and the endothelial protei

32 Mouse embryos lacking protease-activated receptors 1 and 2 showed defective hi

33 tion by thrombin and tryptase is mediated by protease-activated receptors 1 and 2, respectively.

34 s and gene expression profiles by activating protease-activated receptors 1 and 3.

35 an platelets express two thrombin receptors, protease-activated receptors 1 and 4 (PAR1 and PAR4) and

36 Protease-activated receptors 1 and 4 (PAR1 and PAR4) med

37 activates platelets by binding and cleaving protease-activated receptors 1 and 4 (PAR1 and PAR4).

38 acids for alpha-thrombin's interaction with protease-activated receptors 1 and 4 (PAR1 and PAR4, res

39 telets revealed that DXA3 formation requires protease-activated receptors 1 and 4, cytosolic phosphol

40 derived from the third intracellular loop of protease-activated receptors-1 and -2 and melanocortin-4

41 is externalized via calcium mobilization and protease-activated receptors-1 and -4, and 48% is contai

42 These data show promise for protease-activated receptor 1 antagonism in patients und

43 population with symptomatic PAD and whether protease-activated receptor 1 antagonism with vorapaxar

44 The beneficial effects of protease-activated receptor-1 antagonism on limb vascula

45 Protease-activated receptor-1 antagonism was used to tes

46 Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes

47 This study evaluated effects of protease-activated receptor-1 antagonist vorapaxar (Merc

48 elets by alternate mechanisms, including the protease-activated receptor-1 antagonist vorapaxar, have

49 ty and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist.

50 itor leupeptin or two structurally different protease-activated receptor-1 antagonists (SCH79797 and

51 llebrand factor aptamers, thrombin receptor (protease-activated receptor-1) antagonists, and thrombox

52 d the N terminus of thrombin-activated human protease-activated receptor 1 as a controllable proxy sy

53 Last, our analysis identified PAR1 (protease-activated receptor 1) as a potential therapeuti

54 ay partly mediate its pathogenic effects via protease-activated receptor-1, because antagonism of thi

55 thrombo-resistance, excessive activation of protease-activated receptor-1 by thrombin, and insuffici

56 PAR1 (protease-activated receptor-1) contributes to acute thro

57 ver, the endothelial protein C receptor- and protease-activated receptor-1-dependent protective signa

58 Ubiquitination of protease-activated receptor-1 drives recruitment of tran

59 ing activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1)

60 oreover, an antibody to the thrombin site on protease-activated receptor-1 failed to block factor XII

61 Platelets activated through protease-activated receptor 1, FcgammaRIIA, or by treatm

62 exploring the mechanisms, we found that the protease-activated receptor 1-Galpha protein q/11 (Galph

63 ing the thrombin-activatable receptor PAR-1 (protease-activated receptor-1), in Runx1/Cbfb-deleted ML

64 Thus, protease-activated receptor-1-induced protein kinase Cal

65 Thrombin activation of protease-activated receptor-1 induces Ca(2+) influx thro

66 ion of tissue factor, von Willebrand factor, protease-activated receptor-1, intercellular adhesion mo

67 The thrombin-activated GPCR protease-activated receptor-1 is modified by ubiquitin.

68 Thrombin treatment of protease-activated receptor 1 leader/AGPCR fusion protei

69 FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet acti

70 Induction by thrombin was protease-activated receptor-1-mediated, protein synthesi

71 g to several Gq-coupled receptors, including protease activated receptor 1, muscarinic acetylcholine

72 n-induced cleavage and shedding of the human protease-activated receptor 1 NTF increased intracellula

73 gonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets.

74 or, low-density lipoprotein-related protein, protease-activated receptor-1, or matrix metalloproteina

75 Although recent studies established that protease activated receptor 1 (PAR-1) mediates some of t

76 SB2-flot-2 cells had increased expression of protease activated receptor 1 (PAR-1) mRNA, a transmembr

77 ial protein C receptor-dependent cleavage of protease activated receptor 1 (PAR-1) on endothelial cel

78 actor (TF)-dependent thrombin generation and protease activated receptor-1 (PAR-1) activation contrib

79 s of shear stress on the expression of human protease activated receptor-1 (PAR-1) and tissue plasmin

80 hrombin generation and the thrombin receptor protease activated receptor-1 (PAR-1) contribute to live

81 Protease activated receptor-1 (PAR-1) is activated by MM

82 The thrombin receptor protease activated receptor-1 (PAR-1) is overexpressed i

83 Deficiency of either protease activated receptor-1 (PAR-1) or protease activa

84 to generate sickle mice deficient in either protease activated receptor-1 (PAR-1) or protease activa

85 MMP-1 proteolytically activates protease activated receptor-1 (PAR-1), a thrombin recept

86 hibition of the principal thrombin receptor, protease activated receptor-1 (PAR-1), as well as defici

87 is response was dependent upon activation of protease activated receptor-1 (PAR-1).

88 The protease-activated receptor 1 (PAR(1)) plays a key role

89 FLD, we tested whether the thrombin receptor protease-activated receptor 1 (PAR-1) and hematopoietic

90 previously reported that thrombin activates protease-activated receptor 1 (PAR-1) and induces a myof

91 ism of Xa in a HeLa cell line that expresses protease-activated receptor 1 (PAR-1) but not PAR-2, -3,

92 epidermal growth factor receptor (EGFR) and protease-activated receptor 1 (PAR-1) in endothelial cel

93 Protease-activated receptor 1 (PAR-1) mediates thrombin

94 tein C receptor (EPCR)-dependent cleavage of protease-activated receptor 1 (PAR-1) on endothelial cel

95 tein C receptor (EPCR)-dependent cleavage of protease-activated receptor 1 (PAR-1) on vascular endoth

96 for the thrombin G protein-coupled receptor (protease-activated receptor 1 (PAR-1)).

97 Human platelets were treated with protease-activated receptor 1 (PAR-1)-activating peptide

98 osphate [DFP]-thrombin) and mediated via the protease-activated receptor 1 (PAR-1).

99 ion of thrombin is mediated by activation of protease-activated receptor 1 (PAR-1).

100 Protease-activated receptor-1 (PAR(1)) is a G-protein-co

101 eruli, aPC preserves endothelial cells via a protease-activated receptor-1 (PAR-1) and endothelial pr

102 Thrombin activates protease-activated receptor-1 (PAR-1) and engages signal

103 Increasing evidence implicates the protease-activated receptor-1 (PAR-1) as a contributor t

104 Thrombin activates protease-activated receptor-1 (PAR-1) by cleavage of the

105 wo targets of thrombin-mediated proteolysis, protease-activated receptor-1 (PAR-1) expressed by strom

106 expression results in overexpression of the protease-activated receptor-1 (PAR-1) in human melanoma

107 anges in endothelial thrombomodulin (TM) and protease-activated receptor-1 (PAR-1) in irradiated inte

108 Protease-activated receptor-1 (PAR-1) is a key player in

109 Protease-activated receptor-1 (PAR-1) is the high-affini

110 Inhibition of neutrophil elastase and protease-activated receptor-1 (PAR-1) mitigates IL-6 and

111 hrombin activation of the G-protein-coupled, protease-activated receptor-1 (PAR-1) on THBS1 gene expr

112 ive properties, the latter via modulation of protease-activated receptor-1 (PAR-1) signaling.

113 T were significantly blocked in vitro by the protease-activated receptor-1 (PAR-1) silencing RNA; by

114 ttenuates signaling by the thrombin receptor protease-activated receptor-1 (PAR-1) through direct act

115 Protease-activated receptor-1 (PAR-1) was localized to a

116 Tissue factor (TF) and protease-activated receptor-1 (PAR-1) were highly expres

117 ar protease signalling system, including the protease-activated receptor-1 (PAR-1) whose tethered lig

118 eceptor for thrombin on endothelial cells is protease-activated receptor-1 (PAR-1), a member of the G

119 ological response to thrombin is mediated by protease-activated receptor-1 (PAR-1), a seven-transmemb

120 sed a selective agonist (TFLLR-NH(2)) of the protease-activated receptor-1 (PAR-1), a thrombin recept

121 ed endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), as did its in viv

122 The thrombin receptor, protease-activated receptor-1 (PAR-1), plays a key role

123 Agonist peptide for murine protease-activated receptor-1 (PAR-1), which selectively

124 phorylation on serine residues and prevented protease-activated receptor-1 (PAR-1)-induced Ca(2+) ent

125 tes is mediated by proteolytic activation of protease-activated receptor-1 (PAR-1).

126 volve the endothelial protein C receptor and protease-activated receptor-1 (PAR-1).

127 mbilical vein endothelial cells (HUVECs) via protease-activated receptor-1 (PAR-1).

128 the nervous system through the activation of protease-activated receptor-1 (PAR-1).

129 c activation of the major thrombin receptor, protease-activated receptor-1 (PAR-1).

130 c kidney 293 cells through the activation of protease-activated receptor-1 (PAR-1).

131 ed the involvement of the thrombin receptor [protease-activated receptor-1 (PAR-1)] in astrogliosis,

132 The thrombin receptor [protease-activated receptor-1 (PAR-1)] is overexpressed

133 Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that in

134 Structurally novel thrombin receptor (protease activated receptor 1, PAR-1) antagonists based

135 EGF receptor (EGFR) and a thrombin receptor (protease-activated receptor-1, PAR-1) increases the expr

136 nce demonstrates that the thrombin receptor (protease-activated receptor-1, PAR-1) plays a major role

137 , neurogenesis and brain repair were lost in protease activated receptor 1 (PAR1) deficient mice.

138 Here we demonstrate Protease Activated Receptor 1 (PAR1) is an important reg

139 and requires the APC active site, EPCR, and protease activated receptor 1 (PAR1) on endothelial cell

140 eptor (EPCR) as a coreceptor for cleavage of protease activated receptor 1 (PAR1) on endothelial cell

141 Protease activated receptor 1 (PAR1) signaling can play

142 et age (IPF, FSC) and activation through the protease activated receptor 1 (PAR1) thrombin receptor (

143 -out of the thrombin receptor, also known as Protease Activated Receptor 1 (PAR1), accelerates myelin

144 us-encoded glycoprotein C (gC) can stimulate protease activated receptor 1 (PAR1)-enhanced infection

145 rmeability induced by the thrombin receptor, protease activated receptor 1 (PAR1).

146 l protein C receptor-dependent activation of protease activated receptor 1 (PAR1).

147 nced signaling through the G-protein coupled protease activated receptor 1 (PAR1).

148 nt to the blood via two pathways mediated by protease activated receptor 1 (PAR1).

149 he endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR1).

150 Protease activated receptor-1 (PAR1) activation by throm

151 R on endothelial cells, activates endogenous protease activated receptor-1 (PAR1) and induces PAR1-me

152 al protein C receptor (EPCR) and cleavage of protease activated receptor-1 (PAR1) and that may play a

153 blood coagulation protease thrombin through protease activated receptor-1 (PAR1) can disrupt endothe

154 pose that APC-mediated signaling through the protease activated receptor-1 (PAR1) can favorably regul

155 signaling pathway for the thrombin receptor protease activated receptor-1 (PAR1) in human platelets.

156 enase and activator of the G protein-coupled protease activated receptor-1 (PAR1), is an emerging new

157 Proteolysis of the thrombin receptor, protease activated receptor-1 (PAR1), may enhance normal

158 signals in endothelial cells ex vivo through protease activated receptor-1 (PAR1).

159 toprotective signaling through activation of protease activated receptor-1 (PAR1).

160 l cell protein C receptor (EPCR, PROCR), and protease activated receptor-1 (PAR1, F2R) on the growth

161 typical p38 activation via thrombin-mediated protease-activated receptor 1 (PAR1) activity led to enh

162 Activation of protease-activated receptor 1 (PAR1) and PAR2 by specifi

163 ized to promote inflammation via cleavage of protease-activated receptor 1 (PAR1) and PAR2.

164 s callosum in middle-aged mice by activating protease-activated receptor 1 (PAR1) and PAR3.

165 ion and CGRP release could be inhibited by a protease-activated receptor 1 (PAR1) antagonist or prote

166 participation of its principal receptor, the protease-activated receptor 1 (PAR1) appears to be limit

167 WT APC can potentially cleave protease-activated receptor 1 (PAR1) at Arg41 or Arg46,

168 Activation of protease-activated receptor 1 (PAR1) by activated protei

169 following the activation of the cell surface protease-activated receptor 1 (PAR1) by thrombin.

170 Thrombin activates protease-activated receptor 1 (PAR1) faster than proteas

171 Protease-activated receptor 1 (PAR1) has two cleavage si

172 Here we demonstrate that mice lacking protease-activated receptor 1 (PAR1) have a 3.1-fold red

173 -1 has been shown to cleave and activate the protease-activated receptor 1 (PAR1) in noncardiac cells

174 Protease-activated receptor 1 (PAR1) is a G protein-coup

175 Protease-activated receptor 1 (PAR1) is a G protein-coup

176 Protease-activated receptor 1 (PAR1) is a G-protein-coup

177 Protease-activated receptor 1 (PAR1) is a G-protein-coup

178 The G-protein coupled, protease-activated receptor 1 (PAR1) is a membrane prote

179 The G protein-coupled receptor (GPCR) protease-activated receptor 1 (PAR1) is a therapeutic ta

180 Protease-activated receptor 1 (PAR1) is a thrombin-activ

181 The G protein-coupled protease-activated receptor 1 (PAR1) is irreversibly pro

182 Protease-activated receptor 1 (PAR1) is the prototypical

183 Protease-activated receptor 1 (PAR1) is widely expressed

184 onstrate a novel signaling mechanism whereby protease-activated receptor 1 (PAR1) mediates expression

185 Thrombin activates protease-activated receptor 1 (PAR1) on endothelial cell

186 cGVHD was mediated by a biased signaling of protease-activated receptor 1 (PAR1) on T lymphocytes.

187 By contrast, deficiencies of protease-activated receptor 1 (PAR1) or PAR2 did not pro

188 des based on the third intracellular loop of protease-activated receptor 1 (PAR1) or PAR4 (refs.

189 they disrupt signaling through the platelet protease-activated receptor 1 (PAR1) receptor.

190 using variants of human APC with or without protease-activated receptor 1 (PAR1) signaling function

191 of thrombin, and is associated with altered protease-activated receptor 1 (PAR1) signaling, as PAR1

192 Here we show that protease-activated receptor 1 (PAR1) signalling sustains

193 lso acts as a signaling molecule by cleaving protease-activated receptor 1 (PAR1) to cause breast can

194 t protease that initiates cell signaling via protease-activated receptor 1 (PAR1) to regulate vascula

195 We found that protease-activated receptor 1 (PAR1) was transiently ind

196 Protease-activated receptor 1 (PAR1), a G protein-couple

197 Increased expression of protease-activated receptor 1 (PAR1), a G protein-couple

198 Protease-activated receptor 1 (PAR1), a G protein-couple

199 Protease-activated receptor 1 (PAR1), a G protein-couple

200 We previously showed that protease-activated receptor 1 (PAR1), a G protein-couple

201 Protease-activated receptor 1 (PAR1), a G-protein couple

202 se thrombin mediates its effects by cleaving protease-activated receptor 1 (PAR1), a receptor abundan

203 Protease-activated receptor 1 (PAR1), a thrombin-respons

204 We show that thrombin, and other agonists of protease-activated receptor 1 (PAR1), activate TGF-beta

205 Protease-activated receptor 1 (PAR1), an important regul

206 The G protein-coupled thrombin receptor, protease-activated receptor 1 (PAR1), mediates many of t

207 Thrombin activates platelets mainly through protease-activated receptor 1 (PAR1), PAR4, and glycopro

208 by cleaving its G-protein-coupled receptors, protease-activated receptor 1 (PAR1), PAR4, or both.

209 of mice deficient in the thrombin receptor, protease-activated receptor 1 (PAR1), provided definitiv

210 CFs express 190 GPCRs and that activation of protease-activated receptor 1 (PAR1), the most highly ex

211 othelial cytoprotective actions that require protease-activated receptor 1 (PAR1), whereas thrombin a

212 gests that CXCR4 activation reduces thrombin/protease-activated receptor 1 (PAR1)-induced impairment

213 l cell protein C receptor (EPCR) and induces protease-activated receptor 1 (PAR1)-mediated biased sig

214 coagulation cascade and a potent trigger of protease-activated receptor 1 (PAR1)-mediated platelet a

215 dothelial cell protein C receptor (EPCR) and protease-activated receptor 1 (PAR1).

216 tion of serine proteases could overstimulate protease-activated receptor 1 (PAR1).

217 signaling function of aPC, mediated through protease-activated receptor-1 (PAR1) and endothelial pro

218 (aPC), a promising therapeutic, signals via protease-activated receptor-1 (PAR1) and mediates severa

219 Toward identifying the roles of protease-activated receptor-1 (PAR1) and other G protein

220 synthesis in neuronal cells by APC required protease-activated receptor-1 (PAR1) and PAR3, which inh

221 Protease-activated receptor-1 (PAR1) contains five N-lin

222 Protease-activated receptor-1 (PAR1) couples the coagula

223 Protease-activated receptor-1 (PAR1) has been shown to p

224 rect oncogenic activity by signaling through protease-activated receptor-1 (PAR1) in carcinoma cells;

225 lood, Aisiku et al describe a novel class of protease-activated receptor-1 (PAR1) inhibitors that blo

226 Protease-activated receptor-1 (PAR1) is a G protein-coup

227 Protease-activated receptor-1 (PAR1) is a G protein-coup

228 Protease-activated receptor-1 (PAR1) is a G protein-coup

229 Protease-activated receptor-1 (PAR1) is a G protein-coup

230 Protease-activated receptor-1 (PAR1) is a G-protein-coup

231 Protease-activated receptor-1 (PAR1) is a guanine nucleo

232 activation of the G protein-coupled receptor protease-activated receptor-1 (PAR1) is an important sti

233 Protease-activated receptor-1 (PAR1) is highly expressed

234 Protease-activated receptor-1 (PAR1) is important for ac

235 Protease-activated receptor-1 (PAR1) is the principal th

236 and thermodynamic parameters for individual protease-activated receptor-1 (PAR1) molecules in the ab

237 We show that platelet MMP-1 activates protease-activated receptor-1 (PAR1) on the surface of p

238 Contrary to this view, we show that protease-activated receptor-1 (PAR1) promotes contrastin

239 procoagulant protease, cleaves and activates protease-activated receptor-1 (PAR1) to promote inflamma

240 llular (i3) loop agonist, pepducin, based on protease-activated receptor-1 (PAR1) was solved by NMR a

241 Protease-activated receptor-1 (PAR1), a G protein-couple

242 protease, can trigger cellular responses via protease-activated receptor-1 (PAR1), a G protein-couple

243 Protease-activated receptor-1 (PAR1), a G protein-couple

244 The N-terminal exodomain of protease-activated receptor-1 (PAR1), a G protein-couple

245 Degradation or "down-regulation" of protease-activated receptor-1 (PAR1), a G protein-couple

246 Protease-activated receptor-1 (PAR1), a G protein-couple

247 This is exemplified by protease-activated receptor-1 (PAR1), a G protein-couple

248 Signaling by protease-activated receptor-1 (PAR1), a G protein-couple

249 Protease-activated receptor-1 (PAR1), a GPCR activated b

250 Phosphorylation of protease-activated receptor-1 (PAR1), a GPCR for thrombi

251 tein ALIX regulates lysosomal degradation of protease-activated receptor-1 (PAR1), a GPCR for thrombi

252 entified the prototypical thrombin receptor, protease-activated receptor-1 (PAR1), as part of a novel

253 ular protease signaling system including the protease-activated receptor-1 (PAR1), for which thrombin

254 rotein-coupled receptor (GPCR) for thrombin, protease-activated receptor-1 (PAR1), is activated when

255 d facilitated APC cleavage and activation of protease-activated receptor-1 (PAR1), leading to enhance

256 irreversible proteolytic mechanism by which protease-activated receptor-1 (PAR1), the G protein-coup

257 protein-coupled receptors (GPCRs), including protease-activated receptor-1 (PAR1), to elicit inflamma

258 assess SNX1 function in endocytic sorting of protease-activated receptor-1 (PAR1), we used siRNA to d

259 endothelial barrier protective responses via protease-activated receptor-1 (PAR1)-mediated, biased si

260 s endothelial cell signaling by cleaving the protease-activated receptor-1 (PAR1).

261 derived histamine and binding of thrombin to protease-activated receptor-1 (PAR1).

262 hrough G protein-coupled receptors including protease-activated receptor-1 (PAR1).

263 sition and activates human platelets through protease-activated receptor-1 (PAR1).

264 rotein C-endothelial cell protein C receptor-protease activated receptor 1 pathway on endothelial cel

265 viously demonstrated that the stimulation of protease activated receptor 1 promotes alphavbeta6 integ

266 fferences at the transcript level, including protease activated receptor-1, protease activated recept

267 A (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as comp

268 Deficiency in the thrombin receptor protease activated receptor-1 reduces hepatic inflammati

269 Both thrombin and a protease-activated receptor-1-specific agonist peptide i

270 Senescing cells upregulate thrombomodulin-protease-activated receptor-1 (THBD-PAR1) signaling to r

271 Protease activated receptor-1, the presumptive thrombin

272 Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for

273 Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for

274 Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagoni

275 us-forming activity of one of its receptors, protease-activated receptor-1, to dissect how this recep

276 thermore, MMP-1 induced vasoconstriction via protease-activated receptor-1, whose expression was sign

277 tory of myocardial infarction, inhibition of protease-activated receptor 1 with vorapaxar reduces the

278 by proteolytic cleavage on activation of the protease activated receptor-1, with antiangiogenic prope